A new C-terminal hERG mutation A915fs+47X associated with symptomatic LQT2 and auditory-trigger syncope.

Georges Christé, Olivier Thériault, Mohamed Chahine, Gilles Millat, Claire Rodriguez-Lafrasse, Robert Rousson, Isabelle Deschênes, Eckhard Ficker, Philippe Chevalier

To cite this version:
A new C-terminal hERG mutation A915fs+47X associated with symptomatic LQT2 and auditory-trigger syncope

Georges Christé, PhD,* Olivier Thériault, MS,† Mohamed Chahine, PhD,‡ Gilles Millat, PhD,¶§ Claire Rodriguez-Lafrasse, PhD, ¶§ Robert Rousson, MD, PhD,‖ Isabelle Deschênes¶, PhD, Eckhard Ficker, PhD⁷, Philippe Chevalier, MD, PhD⁺§
Abstract

**Background:** A novel mutation of hERG (A915fs+47X) was discovered in a 32 year-old woman with torsades de pointes, long QTc interval (515 ms) and syncope upon auditory trigger. **Objective:** We explored whether the properties of this mutation could explain the pathology. **Methods:** Western blots and sedimentation analysis of del/WT hERG were used to analyze protein expression, assembly and trafficking. Whole-cell A915fs+47X (del) and wild-type (WT) currents were recorded in transiently transfected COS7 cells or Xenopus oocytes.

**Results:** The tail current density at -40 mV after a 2 s depolarisation to +40 mV in COS7 cells expressing del was 36% of that for WT. Inactivation was 1.9-fold to 2.8-fold faster in del versus WT between -60 and +60 mV. In the range -60 to -10 mV, we found that a non-deactivating fraction of current was increased in del at the expense of a rapidly deactivating fraction, with a slowly deactivating fraction being unchanged. In *Xenopus* oocytes, expression of del alone produced 38% of WT currents whereas co-expression of 1/2 WT + 1/2 del produced 49.8%. Furthermore, the expression of del protein at the cell surface was reduced by about 50%. This suggests that a partial trafficking defect of del contributes to the reduction in del current densities and to the dominant negative effect when co-expressed with WT. In model simulations the mutation causes a 10% prolongation of action potential duration.

**Conclusions:** Decreased current levels due to a trafficking defect may explain the long QT syndrome observed in our patient.

**Keywords**

Long QT syndrome; Congenital defects; K-channel; Sudden death; Ventricular arrhythmias; human ether-à-go-go
Introduction

The long QT syndrome results from mutations that are classified in ten classes (LQT1 to LQT10) according to the 10 different genes in which mutations have been identified\textsuperscript{1,2}. LQT2 is the second most common variant of LQTS and accounts for 35%-40% of all mutations. It is related to mutations of the hERG (KCNH2) gene that cause a reduction of the rapid delayed rectifier current, \(I_K\), a major determinant of ventricular action potential repolarization. This predisposes to arrhythmias causing syncope and occasionally sudden death. There is a strong link of auditory trigger for syncope in patients bearing a hERG mutation as compared to mutations in KCNQ1 (LQT1)\textsuperscript{3}.

Many studies have contributed to our understanding of the molecular mechanisms involved in hERG channel dysfunction. Functional characterization of each mutation is important since it may help design therapeutic approaches adapted to the patient's mutational context\textsuperscript{4,5,6}. In this work, we explore whether the electrophysiological properties of a novel C-terminal truncation mutation of hERG, found in a French family from Lyon, may account for the clinical phenotype and compare its properties with those of other C-terminal mutations.

Methods

Engineering of plasmid cDNA

\(hERG\) cDNA in pcDNA3 expression vector (kindly provided by G. Robertson) was co-transfected with the surface marker protein CD8 expression vector (EBO-pcD-CD8). The mutation \(hERG/del-2742-2775\) was introduced into a pcDNA3 vector using a QuickChange\textsuperscript{TM} site-directed mutagenesis kit according to the manufacturer's instructions (Stratagene, La Jolla, CA, USA), using the following nucleotide mutagenic sense and antisense primers:
hERG-del-2742-2775/F (cggcctggggccgggccgggcggccgtggggggagagcccgtccagtg) and hERG-del-2742-2775/R (cactggacgggctctccccccacggcccgcccggcccggcccaaggccg).

Expression and electrophysiological studies in COS7 cells and Xenopus Oocytes

The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).

COS7 cells were plated at 30,000 cells per 35 mm diameter Petri dish in 1.5 ml DMEM. On the next day, every culture dish received 1 µg of either hERG/WT (WT) or hERG/A915fs+47X (del) plasmid, together with 0.05 µg of CD8 plasmid mixed with 3 µl FuGENE 6 (ROCHE Diagnostics Corp.) in 100 µl DMEM without serum. As a control named NoH, some dishes were processed identically but plasmids were omitted. Cells were incubated at 37°C (5% CO2 in air) for 2 days before electrophysiological measurements.

A patch clamp amplifier (BioLogic RK400, Biologic, Meylan, France) was connected through a Labmaster 100 (Axon Instruments) AD/DA board, to a 486-SX based PC computer under Windows v3.11. Voltage-clamp was controlled by the CLAMPEX software of the pCLAMP package (version 4.0, Axon Instruments). Patch pipettes were pulled to an initial resistance of 0.5 to 1 MΩ when filled with intracellular solution containing (mM): 150 KCl; 2 MgCl2; 5 EGTA, 10 HEPES (pH=7.2, adjusted with KOH). Cells were exposed to anti-CD8-coated beads for 5 min (Dynabeads M-450 CD8, Dynal, Oslo, Norway) and washed twice with the bath solution to eliminate the unbound beads. Only cells decorated with beads were used for electrophysiological measurements, done at room temperature (20 to 22°C). Cells were superfused with an external solution containing (mM): 145 NaCl; 5 KCl; 2 MgCl2; 1 CaCl2; 10 HEPES (pH 7.4, adjusted with NaOH). The pipette junction voltage was estimated to 4.2 mV (JPCalc software, Peter H. Barry) and was not corrected for in the analyses. Cell capacitance (Cm) was estimated 7 by fitting a single exponential function to the average of 20
hyperpolarizing pulses (10 mV) from -80 mV. Current densities (in pA/pF) were computed as the ratio of current to $C_m$ for each cell.

The preparation of *Xenopus* oocytes was done as previously described 8. Briefly, oocytes were subjected to collagenase treatment 2 mg/ml during 2.5-3 hours, stage V or VI oocytes were microinjected with 5 ng capped mRNA encoding either wild type (WT), mutant hERG or both. The oocytes were maintained at 18°C in a 2-fold diluted solution of Leibovitz's L-15 medium (Gibco, Grand Island, N.Y., USA) enriched with 15 mM 4-(2-hydroxyethyl)-1-piperazine-methanesulfonic acid (HEPES, pH 7.6, adjusted with NaOH), 1 mM glutamine, and 50 µg/µl gentamycin. Oocytes were used for experiments 1-3 days after injection.

The macroscopic potassium currents from the mRNA-microinjected oocytes were recorded using voltage-clamp technique with two 3M KCl-filled microelectrodes. Membrane potential was controlled by a Warner oocyte clamp (Warner Instrument Corp., Hamden, CT). Voltage commands were generated by computer using pCLAMP software version 5.5 (Axon Instruments, Inc., Foster City, CA). Currents were filtered at 2 kHz (-3 dB; 4 pole Bessel filter). Solutions: The Ringer's bathing solution contained (mM): 116 NaCl, 2 KCl, 0.9 CaCl$_2$, 2.9 MgCl$_2$, 5 HEPES; pH was adjusted to 7.6 at 22°C with NaOH. Ringer solution was low in Ca$^{2+}$ to reduce the contribution of Ca$^{2+}$ activated chloride currents. All experiments were carried out at room temperature (22°C).

Only experiments pertaining to the coexpression of WT and del hERG were conducted in Xenopus oocytes (Panel E of figure 4). All other electrophysiological experiments were carried out in COS7 cells.

*Western blot analysis.*

The polyclonal anti-hERG antibody (rabbit hERGbasic) used in the present study was raised in rabbits against a C-terminal peptide corresponding to hERG aa residues 883-901 as
previously described\textsuperscript{9}. hERG\textsubscript{basic} antiserum was purified on an affinity column consisting of the C-terminal peptide used for immunization (aa 883-901: RQRKRKLSSFRRRTDKDTEQ). HEK293 cells were transfected with either the \textit{WT} or \textit{del} plasmid using Fugene 6. Two days later, they were solubilized for 1 h at 4 °C in lysis buffer containing 150 mM NaCl, 1 mM EDTA, 50 mM Tris, pH 8.0, 1% Triton X-100 and protease inhibitors (Complete, Roche Diagnostics, Indianapolis, IN). Protein concentrations were determined by the BCA method (Pierce, Rockford, IL). Proteins were separated on SDS polyacrylamide gels, transferred to polyvinylidene difluoride membranes and developed using hERG\textsubscript{basic} antibody followed by ECL Plus (GE Healthcare, Piscataway, NJ).

\textit{Sucrose gradients}

HEK293 cells expressing \textit{WT} or \textit{del} hERG were lysed in Digitonin lysis buffer containing 150 mM NaCl, 10 mM Tris, pH 7.4, 1% digitonin and protease inhibitors (Complete, Roche Diagnostics, Indianapolis, IN). Soluble material (400-800 µg total protein) was layered onto 15-45% sucrose gradients (150 mM NaCl, 10 mM Tris, pH 7.4, 0.1% digitonin). Gradients were made using BIOCOMP Model 117 Gradient Mate (BIOCOMP, Fredericton, NB, Canada) according to the operator’s manual, and centrifuged in a Beckman SW50.1 rotor at 48000 rpm for 16-18hr at 4°C, with brakes fully applied. After centrifugation, 275 µl fractions were collected manually from the top of gradients. Aliquots of individual fractions (150 µl) were concentrated using PAGEprep Protein Clean-Up and Enrichment Kit (Pierce) prior to loading onto a SDS/PAGE gel for Western blotting.

\textit{Computer modelling}

A model of guinea-pig ventricular myocyte\textsuperscript{10} was used, in which the original \(I_{Kr}\) formulation\textsuperscript{11} was modified.
The $I_{Kr}$ model was modified to include three subpopulations of channels with different deactivation kinetics. Channels moved from one subpopulation to the other in a sequential manner:

$$
\begin{align*}
F \xrightarrow{\beta_1/\alpha_1} S \xrightarrow{\beta_2/\alpha_2} N
\end{align*}
$$

($F$: fastly deactivating; $S$: slowly deactivating; $N$: non-deactivating).

The rate constants of interconversion, $\alpha_1$, $\beta_1$, $\alpha_2$ and $\beta_2$ were functions of voltage of the shape: $\alpha = u + v \exp[(V_m - V_h)/s]$ where $u$, $v$, $V_h$ and $s$ are constants and $V_m$ is the membrane voltage.

The voltage-dependent steady-state values of the fraction of channels in each subpopulation are resolved using:

$$
F_\infty = 1/(1 + k_1 + k_1 k_2); \quad N_\infty = k_1 k_2/(1 + k_1 + k_1 k_2); \quad S_\infty = 1 - F_\infty - N_\infty;
$$

with $k_1 = \beta_1/\alpha_1$ and $k_2 = \beta_2/\alpha_2$.

The values of parameters $u$, $v$, $V_h$ and $s$ proper to each of the four rate constants were adjusted so that the steady-state values of the fractions versus voltage fitted experimental data. Transitions between the three populations were assumed instantaneous. All three subpopulations had the same properties of activation, inactivation and recovery from inactivation.

The second change to the $I_{Kr}$ model was to reformulate the time-dependent changes in the inactivation variable ($Yr$) in order to allow the time constant of recovery from inactivation ($\tau_{ri}$) to differ from that of inactivation ($\tau_i$):

$$
\text{if } (Y_{r,\infty} - Y_r) < 0: \quad \frac{dY_r}{dt} = \frac{(Y_{r,\infty} - Y_r)}{\tau_{ri}}, \quad \text{otherwise: } \frac{dY_r}{dt} = \frac{(Y_{r,\infty} - Y_r)}{\tau_{ri}};
$$

where $Y_{r,\infty}$ is the steady-state inactivation variable.

In a similar way, the formulation of time-dependent changes in the activation variable ($Xr$) was altered to allow for the time constant of deactivation ($\tau_{da}$) to differ from that of activation ($\tau_a$):
\[
\text{if } (X_{r\infty} - X_r) > 0: \quad \frac{dX_r}{dt} = \frac{(X_{r\infty} - X_r)}{\tau_a}, \quad \text{otherwise: } \quad \frac{dX_r}{dt} = \frac{(X_{r\infty} - X_r)}{\tau_{da}},
\]

where \(X_{r\infty}\) is the steady-state value of the activation variable. There was one such equation for each of the three deactivation subpopulations, for the non-deactivating subpopulation, \(dX_r/dt\) was set to 0 if \((X_{r\infty} - X_r) \leq 0\).

The steady-state inactivation and activation variables were described by Boltzmann functions of voltage, allowing them to remain unaltered whenever the time constants of inactivation or recovery from inactivation or of activation or deactivation were changed. The time constants of deactivation (separate for each subpopulation) and time constants of activation, inactivation and recovery from inactivation were functions of membrane voltage adjusted to reproduce our data.

The equation for the global \(I_{Kr}\) current was:

\[
I_{Kr} = g_{Kr} \times \left[ K^+ \right]_{e} \times \sqrt{\frac{5.4 \times (V_m - E_{Kr}) \times (A_F + A_S + A_N)}{\left[ K^+ \right]_{e}}}
\]

where \(A_F = Xr_F^3 \times Yr \times F_{\infty}\), \(A_S = Xr_S^3 \times Yr \times S_{\infty}\) and \(A_N = Xr_N^3 \times Yr \times N_{\infty}\) are the respective fractions of channels open in each subpopulation, \(g_{Kr}\) is the maximal conductance of the \(I_{Kr}\) current, \(\left[ K^+ \right]_{e}\) the extracellular K\(^+\) concentration, \(V_m\) the transmembrane voltage and \(E_{Kr}\) the reversal voltage of the \(I_{Kr}\) current. The activation variable was elevated to power 3 to account for the delayed onset of activation.

With proper adjustment of parameters, this formulation satisfactorily reproduced the behaviour of WT or del hERG currents recorded in voltage-clamp at room temperature. To produce action potentials, each kinetic process was adjusted to 37°C by applying the specific voltage shifts and Q10 values defined for hERG channels.
Data analysis and statistics

Analysis of electrophysiological data was done using macros in CLAMPFIT (pCLAMP v6.0, Axon Instruments) and custom programs written under MATLAB (The MathWorks Inc.). Mathematical modelling was done in MATLAB. Statistical tests and final figures were done under Origin 4 (OriginLab Corp., Northampton, MA, USA). Results are expressed as mean ± standard error of the mean (sem), the number of measurements (n) is indicated in parentheses. Unpaired Pearson's t-test was used and the p values are indicated in text and figures.

Results

Clinical background

The proband, a woman, began to experience syncopal events at the age of 18, typically when the telephone rang. At the age of 28, hypokalaemia favoured by self-provoked vomiting caused repeated episodes of torsades de pointes (figure 1A) which were treated with beta-blocker therapy. She presented with a QTc of 515 ms. During a follow-up of 7 years and a therapy with nadolol (40 mg per day) she remained asymptomatic.

Figure 1 near here

Her brother and one of her two sons have a long QT interval without any symptoms (QTc of 475 and 480 msec, respectively). Her paternal aunt has had a history of unexplained syncope. Genetic analyses revealed the presence of a novel C-terminal mutation of hERG in these three members of the proband's family\textsuperscript{14} (see the family pedigree in figure 1B).
**Mutation structure**

In this 34 bp deletion of bases 2742 to 2775, the frameshift leaves aa residue G914 preserved. A premature stop codon occurs at position 2883 of the new base sequence. Thus, an extraneous 47 aa sequence is appended after G914 and replaces the last 245 C-terminal aa of WT hERG.

**Figure 2 near here**

Consequently, del protein has a lower apparent molecular weight on Western blots than WT (figure 2A). While hERG WT is synthesized as a fully-glycosylated cell surface protein of about 160 kDa and a core-glycosylated ER resident form of about 135 kDa, the fully- and core-glycosylated forms of del protein are considerably smaller at about 120 and 100 kDa, respectively. Furthermore, quantitative analysis of 5 independent Western blot experiments (figure 2B) shows that in comparison to WT, less fully-glycosylated del protein is produced on transfection of equivalent amounts of cDNA. Since the deletion in hERG is thought to remove a putative assembly site, we analyzed WT and del assembly status by separating digitonin lysates on a 15-45% sucrose gradient. Figure 2C shows a Western blot analysis of WT and del gradient fractions. Both proteins are distributed in two major peaks with the majority present in the tetrameric peak formed by fractions 13-16. In WT, fractions 6-8 form a smaller yet distinct secondary peak which we equate with channel monomers and dimers. However in del, the relative protein content of fractions 5 to 9 is small, i. e.: del monomers/dimers appear to be shifted to larger molecular weights when compared to the corresponding WT forms as if under non-denaturing conditions the smaller del protein is present in complex with another, currently unknown protein.

Taken together, these data suggest that del channels assemble properly but yet exhibit a partial trafficking defect which is most likely responsible for the reduced whole cell current densities observed with del versus WT in electrophysiological experiments (see below).
Properties of mutated channels hERG/A915fs+47X as compared to hERG/WT in COS7 cells

Current-voltage relations, voltage dependence of steady-state activation and activation time course

Cells expressing hERG/A915fs+47X (del) had a cell capacitance (Cm) similar to that of cells transfected with hERG/WT (WT) as reported in Table 1.

Table 1 near here

Typical current families generated in response to a two-pulse protocol by cells expressing WT or del are illustrated in panels A and B respectively, of figure 3.

Figure 3 near here

The current at the end of the prepulse (2 seconds) is characteristic for hERG with a clear apparent inward rectification (figure 4A). For each cell, the I/V relation of the tail current in pulse P2 (I_{maxP2}, figure 4B) was fitted with a Boltzmann function to evaluate the dependence of the steady-state activation variable on the prepulse voltage (V_{p1}) \(^{15}\). In figure 4C on the right, the normalized currents are superimposed with the fitting function, computed from the mean values of V_{ha} (the voltage for half activation) and of k_{a} (the slope factor) in Table 1. It appears that the voltage dependence of steady-state activation was not affected by the mutation.

Figure 4 near here

The average maximal current density at + 50 mV in pulse P2 (figure 3B and Table 1) was 2.76 fold lower in del than in WT cells.
The time constant of activation was evaluated as indicated in figure 4D. The mutation did not cause any significant change in the activation time constant of the hERG current at voltages from –20 to +60 mV (figure 4D).

Panel E of figure 4 compares the amplitudes of peak tail currents at –40 mV in *Xenopus* oocytes co-injected with *WT* and *del* cDNAs with those of oocytes injected with either *WT* or *del* cDNA. The decrease in current related to the mutation confirms the finding in COS7 cells (see above). These results are further analysed in the discussion.

**Voltage dependence of steady state inactivation**

A 3-pulse protocol was used: a maximally activating 2 sec pulse P1 to +50 mV was followed by a short (24 ms) pulse P2 to a variable voltage level (V_{P2}). The amplitude of the current upon returning to +50 mV was normalized to its maximum for most negative V_{P2} values, after correction for the fast deactivation during P2. The resulting data were fitted by a Boltzmann function characterized by the voltage for half inactivation (V_{hi}) and the slope factor (k_i). These were not significantly different between *del* and *WT* (see values in Table 1). Thus the steady-state inactivation versus voltage relation (see the plots in figure 4C, left traces) is not affected by the mutation.

**Time course of inactivation, reversal voltage and maximal conductance**

A 3-pulse protocol was used. A 2 sec pulse P1 to +40 mV was followed by a 8 ms pulse P2 to –120 mV to relieve inactivation. The fast time constant of current decay in the test pulse (P3) to various voltages evaluated the inactivation time constant. As shown in figure 5 the mutated channel (*del*) inactivates 1.9-fold to 2.8-fold faster than *WT* between -60 and +60 mV.

*Figure 5 near here*
Extrapolation of the fitted curve to time 0 of pulse P3 yielded the instantaneous current-voltage relation (not shown). Its intercept with the voltage axis evaluates the reversal voltage \(E_{\text{rev}}\) of the hERG current (Table 1), which was almost identical in del and WT. Thus, the ionic selectivity of the channel is not changed by the mutation.

**Time course of deactivation of the hERG current**

We recorded the current response during a 5.8 s test pulse at various voltages after a 2 s maximally activating prepulse to +40 mV (see inset to figure 6A). The current shows fast recovery from inactivation, followed by a slower, bi-exponential deactivation. The time constant of recovery from inactivation (figure 6B), was not affected by the mutation. The fast and slow exponential deactivation processes were estimated at all voltages by fitting a two-exponential function plus offset to the current traces from 80 ms to the end of the test pulse:

\[
y = I_{\text{fast}} \cdot \exp\left(-t / \tau_{\text{fast}}\right) + I_{\text{slow}} \cdot \exp\left(-t / \tau_{\text{slow}}\right) + I_{\text{infinity}}
\]

comprising a fast component with amplitude \(I_{\text{fast}}\) and time constant \(\tau_{\text{fast}}\), a slow component with amplitude \(I_{\text{slow}}\) and time constant \(\tau_{\text{slow}}\), \(I_{\text{infinity}}\) being the amplitude of the component that did not deactivate. These parameters were iteratively adjusted using the "Simplex" method within MATLAB until the sum of squared differences with experimental data was minimal.

There was no significant difference at any voltage between del and WT currents in the fast deactivation time constant \((\tau_{\text{fast}})\) or in the slow one \((\tau_{\text{slow}})\) (figure 6C).

*Figure 6 near here*

**Amplitudes of the components of current decay**

We also explored in each cell the voltage dependence of the initial amplitudes of the fast and slow deactivation components and that of the non-deactivating component. An example of this analysis is given in figure 6D where it appears that the sum of the amplitudes of the
three components (thick line) is the fully activated current-voltage relation. We further computed the ratio of each of these three components to the total current in order to evaluate the respective fraction of the current contributed by each of these three processes. The voltage dependence of these fractions is shown in figure 6, (panels E, F, G). It appears that the fast deactivating fraction was significantly lower for del current than for WT at all voltages from -70 to -10 mV. In contrast, the non-deactivating fraction was significantly higher in del than in WT in the same voltage range. The slowly deactivating fraction was slightly changed.

Although the different components of deactivation of WT hERG have been studied in the past 17, a careful quantitative analysis of the relative contribution of fast-, slow- and non-deactivating fractions at various voltages has not been previously reported. We interpreted these changes as due to the distribution of hERG channels among three kinetically differently deactivating subsets (see Methods) and included this concept into a model of single ventricular myocyte to test the impact on AP configuration (see in Discussion).

**Discussion**

To date, about 290 mutations have been found in the hERG gene and related to Romano-Ward Syndrome and Sudden Infant Death Syndrome. Of these mutations, 91 occur in the C-terminal region. The novel mutation found in this study is a frameshift/deletion at aa 915 in the C-terminal region of hERG that removes a putative assembly domain of the channel protein. Among 38 mutations distal to this site, 25 are deletions 18. When co-expressed with WT, mutated hERG proteins may cause a reduction of hERG currents due to altered trafficking 19,20, altered subunit assembly 19, or by rendering heterotetramers dys- or hypo-functional 16.
**Reduced cell surface expression and current density**

Our Western analysis showed that only about half of del hERG attains the fully glycosylated mature state when compared to WT (figure 2A-B). It has been shown previously that the fully-glycosylated form of hERG is located at the cell surface \(^{21,22}\). Thus, the observed reduction in the fully-glycosylated protein form of del is mainly responsible for the lower membrane current densities observed in COS7 cells (36%; figure 4B and Table 1) as well as in *Xenopus* oocytes (37%; figure 4E). The phenotype of del was further evaluated upon co-expression with WT, to mimic the heterozygous state found in our patient. Co-injection of 2.5 ng del + 2.5 ng WT cDNA in Xenopus oocytes yielded peak tail current densities that represented about 48% of those recorded on injection of 5 ng WT cDNA. In contrast, injection of 5 ng del cDNA yielded 37% of the tail current densities observed with 5 ng WT. If del and WT were not be able to co-assemble and expressed currents independently, we would expect 68.5% (50% WT + 37/2% del) of WT currents assuming that the amount of hERG current generated per oocyte is proportional to the amount of cDNA injected \(^{23}\). Thus, co-expression decreased hERG current density when compared to independently expressing del and WT subunits, but increased current density when compared to del expressed in isolation. This complex behaviour is explained best with co-assembly of del and WT channel subunits into heterotetramers. Heterotetramer formation is not unlikely, since fractionation experiments of del on sucrose gradients have shown that the assembly of del subunits into tetramers was not compromised (fig 2C). Using a binomial formula \(^{24}\), and assuming that the presence of one or more del subunit in a tetramer reduces its trafficking to 50% (or to 37%), the overall current when \(\frac{1}{2}\) WT and \(\frac{1}{2}\) del are co-expressed is 53% (respectively 42%) of that with WT alone. The value of 48% found in our co-expression experiments agrees with this view. Taken together, our data suggest that WT and trafficking-deficient del subunits most
likely assemble into trafficking-deficient heterotetramers thereby producing a dominant negative effect.

The assembly of del into tetramers is somewhat unexpected, since the TCC (tetramerizing coiled-coil) domain - found within aa region 1018-1122\textsuperscript{19} - is absent in hERG/A915fs+47X. Nevertheless, the sucrose gradient data clearly indicate that assembly is not affected in del, confirming that the TCC may not be an absolute requirement for proper tetramer formation\textsuperscript{19}. At the same time, the deletion seems to produce a small shift on sucrose gradients in line with the formation of novel protein-protein interactions, possibly with components of the cellular quality control machinery, which may be ultimately responsible for the reduced surface expression of del or del/WT heterotetramers.

Comparison with other C-terminal truncation mutations

Another C-terminal truncation, R1014X, has also been associated with a trafficking defect in combination with a strong dominant negative effect exerted on WT hERG, while tetrameric assembly was not impaired\textsuperscript{19}. Despite the fact that del (A915fs+47X) removes a much larger part of the C-terminus (245 aa) than R1014X (146 aa), the reduction in current density was less pronounced. Thus, functional effects of a particular deletion may not simply correlate with the extent of the deletion. In addition, del was also characterized by a 2-fold acceleration of current inactivation. Although a number of C-terminal mutations were found in LQT2 patients, only few have been characterized at the functional level\textsuperscript{18}. For example, the deletion of up to 215 aa had no effects on biophysical properties, whereas deletion of either 236 or 278 aa accelerated current deactivation and speeded up recovery from inactivation\textsuperscript{25}. In marked contrast, removal of 245 aa in del did not alter any of these parameters. Similarly, neither G965X nor R1014PfsX39 or V1038AfsX21, three other C-terminal deletions found in LQT2 patients, changed current kinetics, with only G965X decreasing current amplitudes (33% of
WT hERG)\textsuperscript{26}. Finally, the two-fold acceleration of current inactivation in del is rather unique. Only one other C-terminal deletion/frameshift mutation has been described so far (hERG 1122fs/147) that accelerated current inactivation in a similar manner\textsuperscript{27}. Interestingly, the replacement of the last 37 C-terminal aa by a 147 extraneous aa sequence was responsible for this phenomenon in hERG 1122fs/147\textsuperscript{27}. Likewise, addition of an extraneous sequence of 47 aa in del may play a role in the altered biophysical properties of this channel. While these results suggest that the hERG C-terminus contributes to channel inactivation, a mechanistic explanation is currently not at hand.

**Proarrhythmic consequences of the mutation**

The three changes caused by the del mutation, -decreased current density, accelerated inactivation and modified pattern of deactivation kinetics-, were introduced in a computer model with a modified formulation of I_{Kr} (see Methods). This model was used to evaluate the effects of the mutation-induced changes on the ventricular action potential (AP).

*Figure 7 near here*

Starting from a control action potential (AP) elicited at 1 Hz (see bar 1 in figure 7A), wildtype I_{Kr} parameters were altered to reproduce various combinations of the effects observed for the del mutation (see the legend to figure 7). Introduction of accelerated inactivation (bar 2), of altered deactivation (bar 3), or of both altered inactivation and deactivation parameters (bar 4), slightly shortened the duration to 90% repolarization (APD\textsubscript{90}) of the following AP. In contrast, a two-fold decrease of the maximal conductance of I_{Kr} (bar 5) considerably lengthened APD\textsubscript{90} as compared to WT (bar 1). When accelerated inactivation (bar 6) and altered deactivation (bar 7) were also added, APD\textsubscript{90} was unchanged or slightly shortened versus decreased I_{Kr} conductance alone (bar 5). When all mutation-induced changes were introduced simultaneously, APD lengthening (bar 8 versus bar 1) was similar to what
was observed when only the $I_{Kr}$ conductance was decreased (bar 5 versus bar 1). The accelerated inactivation caused by the mutation did not change the time course of the action potential since inactivation reaches its steady-state within 12 ms (3 x time constant of 4 ms at +30 mV), and within 5 ms when inactivation is accelerated 2.5-fold. Since steady-state inactivation is not altered by the mutation, the amount of current carried by hERG should only be decreased at very early time points of the AP when inward currents dominate. The change in current deactivation does also not influence AP duration because at voltages corresponding to the AP plateau, most channels are in the slow- and non-deactivating fractions, so that overall deactivation during an AP is negligible. Taken together, the most prominent effect of the mutation on AP duration is attributable to the decrease of $I_{Kr}$ current amplitude which reflects mostly disrupted channel trafficking.

The effect of all the mutation-induced changes on the AP and the concomitant $I_{Kr}$ current (figure 4B and 4C) is reflected in an AP prolongation of 9.6% when compared to WT. This could account for the LQT phenotype observed and would explain the increased susceptibility to triggers of early after-depolarisations involved in torsades de pointes and related syncope seen in our patient.

**Conclusion**

This novel heterozygous A915fs+47X mutation alters several biophysical hERG channel properties and produces a pronounced trafficking defect which underlies its dominant negative behaviour. As a result, $I_{Kr}$ currents are reduced by 50% which may explain the proarrhythmic events observed in our patient.
Acknowledgements

This work was supported by a research grant to G. Christé from the Fédération des Maladies Orphelines, Paris. G. Christé is grateful to colleagues at the laboratory of "Physiologie Intégrative, Cellulaire et Moléculaire", UMR CNRS 5123, Université Lyon 1, who welcomed him for doing most of the present work. This study was also supported by grants from the Heart and Stroke Foundation of Québec (HSFQ) and the Canadian Institutes of Health Research (CIHR). M. Chahine is an Edwards Senior Investigator (Joseph C. Edwards Foundation).
References


Legends to the table and figures

Table 1: Parameters (mean ± sem) of COS7 cells transfected with either WT or mutated (hERG/A915fs+47X) plasmid. Numbers of cells is indicated in parentheses. *** denotes significant difference of mutant versus WT with P<0.001.

Figure 1: A: Torsade de Pointes triggered by hypokalaemia in the proband. The horizontal bar represents 1 sec. B: Pedigree of the family (squares are males, circles females). The proband is marked with a + sign. Bearers of the mutations are in grey and are labelled 'del'. The family members that were tested and did not bear the mutation are labelled 'WT', numbers are the QTc values in ms.

Figure 2: Protein analysis. A: Typical Western blot produced on transfection of either 0.75 or 1.5 ug cDNA (WT or del mut) in HEK293 cells. The WT hERG protein appears with the expected apparent molecular mass (160 kDa for the fully glycosylated form (fg) and 135 kDa for the core-glycosylated form (cg) of WT). del is considerably smaller at 120 (fg) and 100 kDa (cg) B: For 5 independent experiments, we computed the fg/cg ratio (fg image density) / (cg image density) for WT and for del. The bar diagram represents plots of the averaged fg/cg quotients (n=5) for both WT and del at the two different cDNA concentrations. The del quotients are significantly smaller (* i.e.: p<0.05, n=5) than WT quotients. C: Quantification of sucrose gradient analysis of WT and del proteins. The amount of protein recovered in each of the 24 fractions was quantified as image density on Western blots. Signals from an entire gradient were summed up and set at 100%. Average values of three independent experiments were plotted versus fraction numbers. Fractions 1 to 6 yielded no hERG protein and were not plotted. The analysis depicts two major peaks. The smaller peak to the left represents hERG.
monomers and dimers, while the prominent peak to the right of the plot represents hERG tetramers.

**Figure 3:** Exploration of the current versus voltage relation in response to a two pulse protocol (insets to panels A and B): from a holding voltage at –80 mV, a 2 s duration pulse P1 to a variable voltages between –80 and +60 mV in 10 mV increment was applied, followed by a 2 s test pulse P2 to –40 mV. **A:** currents in a cell transfected with WT. A sum of two exponential functions plus offset was fitted to the current time course during each pulse (solid line). **B:** Representative example of currents recorded from a cell transfected with del.

**Figure 4:** Current-voltage relations in cells expressing hERG/WT (WT), hERG/A915fs+47X (del) or non transfected (NoH), the symbols and lines given in the inset of panel A apply to panels B, C and D. The voltage protocol is shown in figure 1 (inset). The numbers of cells and symbol definitions in panel A apply to panels B and C. **A:** Current measured at the end of the first pulse of the protocol versus pulse voltage. **B:** Maximal current during second pulse plotted versus voltage of first pulse. **C:** The average values of the peak tail current after background current subtraction and normalization are superimposed for WT and del to the steady-state activation variable (f_{act}) versus voltage relations computed using a Boltzmann function and data in table 1. The two lines on the left are the inactivation versus voltage relations reconstructed for WT (dashed line) and for del (solid line) from data in table 1. **D:** Time constants of activation as evaluated using a 2-exponential fit to current traces from 75 ms to end of first pulse (figure 1). Symbols and lines are as defined in A. Dubious fitting results were eliminated and the size of the useful dataset is indicated near to each data point on the graph. **E:** Average peak tail currents in Xenopus oocytes injected with: buffer (open
triangles); 5 ng WT cDNA alone (filled circles); 5 ng del cDNA (open circles); 2.5 ng WT cDNA + 2.5 ng del cDNA (filled triangles). The voltage clamp protocol was the same as for COS7 cells.

**Figure 5**: Time constants of inactivation, as evaluated by fitting a single exponential function to the first 150 ms of the current at the beginning of pulse P3 (not shown, see protocol (3) in methods). Mean ± sem for WT (squares) and for del (circles) are plotted versus voltage during P3. The number near each symbol is the number of cells. *** denotes significant difference of the two means with P<0.001 (Pearson's t-test).

**Figure 6**: Analysis of deactivation kinetics. A: Example of current responses to the protocol (inset) used for evaluating deactivation kinetics. Both the full size response to the second pulse and an expanded view of its initial region are shown. B: Time constant of recovery from inactivation versus voltage. C: Fast (hollow symbols) and slow (filled symbols) time constants of deactivation for WT (squares) and del (circles), plotted along a logarithmic vertical axis, versus second pulse command voltage. D: Example for one cell of the voltage dependence of amplitudes of the fast (squares) and the slow (triangles) exponential components of deactivation and of the infinity value of the current (circles), as resulted from the fits. The thick solid line is their sum and is also the fully activated I/V relation at time zero of pulse P2. E, F and G show the voltage dependence of the three components of current for WT (filled symbols) and del (hollow symbols). The data came from 13 cells expressing WT and 12 cells expressing del. Statistical significance of differences are reported as star signs: * p<0.05; ** p<0.01; *** p<0.001. E: The fraction of current decaying fast. F: The fraction of current decaying slowly. G: The fraction of non-decaying current.
Figure 7: Action potentials (APs) generated by the ventricular cell model. A: the duration of APs at 90% repolarization (APD$_{90}$ as plotted as horizontal bars with exact values in ms at the right) were measured in the following situations. (1): At steady-state (after 100 beats) at 1 Hz with WT $I_{Kr}$. (2 to 5): From the steady-state action potential in case 1, various changes were applied and the APD$_{90}$ of the next AP was measured. The changes were: (2): two-fold faster inactivation (3): altered deactivation pattern; (4): two-fold faster inactivation plus altered deactivation pattern; (5): halved $I_{Kr}$ conductance only; (6): halved $I_{Kr}$ conductance plus two-fold faster inactivation; (7): halved $I_{Kr}$ conductance plus altered deactivation pattern; (8): all of the del mutation-induced changes. B and C respectively show action potential and $I_{Kr}$ waveforms at steady-state either in WT (black lines) or after application of all mutation-related changes (del, grey lines).
<table>
<thead>
<tr>
<th></th>
<th>HERG/WT</th>
<th>HERG/A915fs+47X</th>
</tr>
</thead>
<tbody>
<tr>
<td>$C_m$ (pF)</td>
<td>44.6 ± 3.0 (53)</td>
<td>41.8 ± 1.8 (49)</td>
</tr>
<tr>
<td>Maximal HERG tail current density (pA/pF)</td>
<td>21.64 ± 3.24 (53)</td>
<td>7.83 ± 1.17 (49)***</td>
</tr>
<tr>
<td>Steady state activation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$V_{ha}$ (mV)</td>
<td>-0.2 ± 1.2 (53)</td>
<td>1.9 ± 1.8 (49)</td>
</tr>
<tr>
<td>$k_a$ (mV)</td>
<td>-8.3 ± 0.4 (53)</td>
<td>-8.6 ± 0.6 (49)</td>
</tr>
<tr>
<td>Steady state inactivation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$V_{hi}$ (mV)</td>
<td>-62.9 ± 5.7 (7)</td>
<td>-67.4 ± 1.9 (8)</td>
</tr>
<tr>
<td>$k_i$ (mV)</td>
<td>24.4 ± 1.4 (7)</td>
<td>22.8 ± 1.4 (8)</td>
</tr>
<tr>
<td>$E_{rev}$ from instantaneous I/V</td>
<td>-76.5 ± 0.9 (11)</td>
<td>-77.4 ± 0.4 (18)</td>
</tr>
</tbody>
</table>

Table 1
Figure 1
Figure 2

(A) 

(B) 

(C)
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7